Tongxinluo

Phase 3Small molecule

FFudan University

Tongxinluo is one of 52 small molecule programs targeting Cerebral Small Vessel Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral Small Vessel DiseaseNot yet recruiting

ARTNot yet recruiting

Cerebral Small Vessel DiseasePhase 3

Not yet recruiting

ARTPhase 3

Not yet recruiting

Competition

Competitive Landscape

96 competitors in ART

#DrugCompanyPhaseTrials

Belamaf

GSK

Phase 3

3 2

Venclexta

AbbVie

Phase 3

2 3

Lorelco

Sanofi

Phase 3

1 4

Rituxan

Roche

Phase 3

1 5

Attruby

NNavire Pharma Inc., a BridgeBio company

Phase 3

1 6

Brukinsa

BBeOne Medicines

Phase 3

1 7

Treanda

AAzurity Pharmaceuticals

Phase 3

1 8

Toradol

JJavelin Pharmaceuticals

Phase 3

1 9

Cysteine Hydrochloride

Novartis

Phase 2

1 10

Noradrenaline

IInstitute of Liver and Biliary Sciences, India

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

ART

NCT06112028

Post-ApprovalNot yet recruiting

Cerebral Small Vessel Disease

NCT06061692

Clinical

Trials by Indication[1]

Acute Myocardial Infarction1 trial

China Tongxinluo Study for Myocardial Protection in Patients With Acute Myocardial Infarction

Unknown status·CChina National Center for Cardiovascular Diseases·Phase 4·NCT03792035·3,796 enrolled

Vascular Disease1 trial

Tongxinluo Capsule for Coronary Microvascular Disease

Unknown status·QQilu Hospital of Shandong University·Phase 4·NCT04220372·100 enrolled

Heart Disease1 trial

Tongxinluo Improve High on Clopidogrel Platelet Reactivity Patients With Coronary Heart Disease

Completed·HHan Yaling·Phase 4·NCT01721590·134 enrolled

Ischemic stroke1 trial

Tongxinluo Capsule in Ischemic Stroke Patients（TISS)

Completed·Yyongjun wang·Phase 4·NCT01919671·2,007 enrolled

Cerebral Small Vessel Disease1 trial

Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study（TOPS-CSVD）

Not yet recruiting·FFudan University·Phase 4·NCT06061692·1,052 enrolled

1 more indication

ART1 trial

Clinical Study of Tongxinluo Capsule in Preventing and Treating Restenosis After Intracranial and External Arterial Stenting

Not yet recruiting·YYanbin Li·Phase 4·NCT06112028·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Tongxinluo. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tongxinluo compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tongxinluo. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFudan University

Tongxinluo

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Acute Myocardial Infarction1 trial

Vascular Disease1 trial

Heart Disease1 trial

Ischemic stroke1 trial

Cerebral Small Vessel Disease1 trial

ART1 trial

References

Drug Info

Quick Facts

Related News